Paper Details

  1. Home
  2. Paper Details

Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics.

Author: BoeckhMichael J, EnglundJanet A, LindegardhNiklas, NguyenJack T, PukrittayakameeSasithon, RenaudChristian, SeoSachiko, TambyahPaul A, TarningJoel, WentGregory T, de JongMenno D

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A triple-combination antiviral drug (TCAD) regimen consisting of amantadine (AMT), oseltamivir (OSL) and ribavirin (RBV) demonstrated good efficacy in an animal model for the treatment of drug-resistant influenza A.
Paper Details　
Original Abstract of the Article :
Antiviral resistance among influenza A viruses is associated with high morbidity and mortality in immunocompromised hosts. However, treatment strategies for drug-resistant influenza A are not established. A triple-combination antiviral drug (TCAD) regimen consisting of amantadine (AMT), oseltamivir ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/23264438

データ提供：米国国立医学図書館（NLM）

Combating Antiviral Resistance: A Triple Threat

In the ever-evolving world of [Infectious Diseases], the emergence of antiviral resistance poses a significant challenge. This research, like a team of researchers armed with a potent arsenal of antivirals, explores the safety and pharmacokinetics of a triple-combination antiviral drug (TCAD) regimen consisting of amantadine (AMT), oseltamivir (OSL), and ribavirin (RBV) for the treatment of influenza A infection. The authors, like skilled strategists, carefully evaluate the potential benefits and risks of this multi-drug approach in the fight against drug-resistant influenza A.

A New Frontier in Antiviral Therapy

This research suggests that the TCAD regimen, with its synergistic combination of three antivirals, could potentially offer a promising strategy for managing drug-resistant influenza A infection.

A Multi-Pronged Approach

This research underscores the importance of exploring multi-drug approaches in the fight against antiviral resistance. The TCAD regimen demonstrates the potential of combining multiple antivirals to overcome resistance and improve treatment outcomes.

Dr. Camel's Conclusion

This research, like a desert explorer venturing into uncharted territory, sheds light on the potential of a triple-combination antiviral regimen to combat drug-resistant influenza A infection. The study’s findings provide a valuable reminder that innovative strategies are needed to overcome the growing challenge of antiviral resistance.

Date :
  1. Date Completed 2013-09-20
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

23264438

DOI: Digital Object Identifier

EMS56290

Related Literature

Article Analysis
・Side Effects of oseltamivir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.